ADVISORY, Sept. 09, 2015 (GLOBE NEWSWIRE) —
Alexion Pharmaceuticals, Inc. (Nasdaq:ALXN), a global biopharmaceutical company focused on developing and delivering life-transforming therapies for patients with devastating and rare disorders, will visit the Nasdaq MarketSite in Times Square.
In honor of the occasion, David Hallal, Chief Executive Officer will ring the Closing Bell.
Nasdaq MarketSite – 4 Times Square – 43rd & Broadway – Broadcast Studio
Thursday, September 10, 2015 – 3:45 p.m. to 4:00 p.m. ET
Alexion Media Contacts:
Stephanie Fagan, (203) 271-8223
Senior Vice President, Corporate Communications
Kim Diamond, (203) 439-9600
Executive Director, Corporate Communications
Fiber Line (Encompass Waterfront): 4463
Gal 3C/06C 95.05 degrees West
18 mhz Lower
DL 3811 Vertical
For multimedia features such as exclusive content, photo postings, status updates and video of bell ceremonies please visit our Facebook page at: http://www.facebook.com/NASDAQ.
For photos from ceremonies and events visit our Instagram Page: http://instagram.com/nasdaq
For news tweets, please visit our Twitter page at: http://twitter.com/nasdaq
For exciting viral content and ceremony photos visit Tumblr Page: http://nasdaq.tumblr.com/
A webcast of the Nasdaq Closing Bell will be available at: https://new.livestream.com/nasdaq/live or http://www.nasdaq.com/about/marketsitetowervideo.asx
To obtain a hi-resolution photograph of the Market Close, please go to http://www.nasdaq.com/reference/marketsite_events.stm and click on the market close of your choice.
About Alexion (Nasdaq:ALXN):
Alexion is a global biopharmaceutical company focused on developing and delivering life-transforming therapies for patients with devastating and rare disorders. Alexion developed and commercializes Soliris® (eculizumab), the first and only approved complement inhibitor to treat patients with paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS), two life-threatening ultra-rare disorders. Alexion is also establishing a premier global metabolic rare disease franchise, which includes Kanuma™ (sebelipase alfa) for patients with lysosomal acid lipase deficiency (LAL-D), and Strensiq™ (asfotase alfa), a late-stage enzyme replacement therapy under investigation for patients with hypophosphatasia (HPP). In addition, Alexion is advancing the most robust rare disease pipeline in the biotech industry, with highly innovative product candidates in multiple therapeutic areas. As the global leader in complement inhibition, the Company is strengthening and broadening its portfolio of complement inhibitors across diverse platforms, including evaluating potential indications for Soliris in additional severe and ultra-rare disorders.
About NASDAQ-100 Index®:
The NASDAQ-100 Index, launched in January 1985, is one of the most widely followed benchmarks in the world. The NASDAQ-100 Index is the basis of the PowerShares QQQ Trust (Nasdaq:QQQ) which aims to provide investment results that, before expenses, correspond with the NASDAQ-100 Index’s performance. In addition, options, futures and structured products based on the NASDAQ-100 Index and the PowerShares QQQ Trust trade on various exchanges.
About Nasdaq Group:
Nasdaq (Nasdaq:NDAQ) is a leading provider of trading, clearing, exchange technology, listing, information and public company services across six continents. Through its diverse portfolio of solutions, Nasdaq enables customers to plan, optimize and execute their business vision with confidence, using proven technologies that provide transparency and insight for navigating today’s global capital markets. As the creator of the world’s first electronic stock market, its technology powers more than 70 marketplaces in 50 countries, and 1 in 10 of the world’s securities transactions. Nasdaq is home to more than 3,600 listed companies with a market value of approximately $9.6 trillion and more than 10,000 corporate clients. To learn more, visit: nasdaq.com/ambition or business.nasdaq.com.